Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis

Gilles Jadd Hoilat, Mohamad Fekredeen Ayas, Judie Noemie Hoilat, Ahmed Abu-Zaid, Ceren Durer, Seren Durer, Talal Adhami, Savio John

Abstract
Background Hepatic encephalopathy (HE) is defined as brain dysfunction that occurs because of acute liver failure or liver cirrhosis and is associated with significant morbidity and mortality. Lactulose is the standard of care till this date; however, polyethylene glycol (PEG) has gained the attention of multiple investigators.

Methods We screened five databases namely PubMed, Scopus, Web of Science, Cochrane Library and Embase from inception to 10 February 2021. Dichotomous and continuous data were analysed using the Mantel-Haenszel and inverse variance methods, respectively, which yielded a meta-analysis comparing PEG versus lactulose in the treatment of HE.

Results Four trials with 229 patients were included. Compared with lactulose, the pooled effect size demonstrated a significantly lower average HE Scoring Algorithm (HESA) Score at 24 hours (Mean difference (MD)=−0.68, 95% CI (−1.05 to −0.31), p<0.001), a higher proportion of patients with reduction of HESA Score by ≥1 grade at 24 hours (RR=4.33, 95% CI (1.17 to 1.67), p<0.001), a higher proportion of patients with a HESA Score of grade 0 at 24 hours (RR=4.33, 95% CI (2.27 to 8.28), p<0.0010) and a shorter time to resolution of HE group (MD=−1.45, 95% CI (−1.72 to −1.18), p<0.001) in favour of patients treated with PEG.

Conclusion PEG leads to a higher drop in the HESA Score and thus leads to a faster resolution of HE compared with lactulose.

Introduction
Advanced liver disease is notorious for its systemic complications, particularly its overwhelming effect on brain function. Hepatic encephalopathy (HE), is defined as brain dysfunction that occurs as a result of acute liver failure or liver cirrhosis and is associated with significant morbidity and mortality. It can manifest as a broad spectrum of reversible neuropsychiatric abnormalities, ranging from change in behaviour or personality, intellectual impairment and altered mentation to coma. It is classified as overt HE (OHE) if clinically evident or minimal HE if apparent through neurophysiologic testing. OHE occurs in 30%–40% of patients with liver cirrhosis and is a frequent cause of hospitalisation; roughly 22 931 hospitalisations occurred secondary to HE in 2009.

One of the main setbacks in early diagnosis and treatment of HE is the lack of a well-validated, gold standard assessment method to detect HE. The most widely used HE grading system till this date is the West Haven Criteria (WHC), which is a subjective method that divides HE into four stages based on changes in intellectual function, level of consciousness, behaviour and neuromuscular signs. Given that it only relies on clinical judgement, it has been heavily criticised for its poor sensitivity in detecting milder forms of HE that are only present with subtle neurocognitive impairments. The HE Scoring Algorithm (HESA) is an adaptation of the WHC that possesses both subjective and objective indicators to measure neuropsychiatric symptoms associated with HE (online supplemental table 1) and seems to offer an advantage over other existing methods as it incorporates a multidimensional approach for the diagnosis of HE.

The exact mechanism that leads to HE remains poorly understood. The most accepted theory describes ammonia as a key player in the pathogenesis of HE. In patients with acute liver failure or portosystemic shunts, a build up of ammonia level in the blood occurs which crosses the blood–brain barrier into the brain and gets metabolised into glutamine by astrocytes. The accumulation of glutamine in the brain increases...
intracellular osmolarity leading to cerebral oedema.8
Since hyperammonemia has been coined the main contributing factor in the pathogenesis of HE, interventions that target lowering blood ammonia level have been the topic of interest in recent studies.

The initial treatment reported in the literature for the management of HE describes the induction of catharsis with magnesium salts.9 It was not until 1966 when Bircher et al9 published a study regarding the use of lactulose, a non-absorbable disaccharide for the treatment of HE that led to the widespread adoption of this approach. A Cochrane systematic review published by Als-Nielsen et al11 determined that there is no sufficient evidence to support or refute the use of lactulose or other non-absorbable disaccharides for the management of HE. Additional treatment options and preventative interventions for HE are needed to reduce its incidence, alleviate the socioeconomic impact on patients and families and mitigate the burden on healthcare resources.

Polyethylene glycol (PEG) is a safe, affordable, widely available and highly effective osmotic laxative that acts as a faecal cleanser for the removal of faecal nitrogen. Several randomised controlled trials (RCTs) evaluated the effectiveness of PEG versus lactulose in the treatment of HE; however, the results were inconsistent.12–15 Herein, we conducted a systematic review and meta-analysis to assess the safety and clinical efficacy of PEG compared with the standard of care lactulose in patients with HE.

METHODS

Study protocol
We followed the steps of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)16 during the conduct of this research.

Literature search strategy
We screened five databases—namely PubMed, Scopus, Web of Science, Cochrane Library and Embase—and additional records were identified through other sources such as Google search—from inception to 10 February 2021. We used the following search strategy in all databases:

Hepatic encephalopathy AND (polyethylene glycol OR PEG 3350 OR PEG3350 OR Carbowax OR Golytely OR GlycoLax OR Fortrans OR TriLyte OR Golyte OR HalNYLyt OR macrogol OR MiraLAX OR Moviprep) AND (lactulose OR Kristalose OR Emulose OR Generlac). There was neither restriction on publication date nor language. Two authors performed the literature search independently and conflicts were resolved by consensus.

Eligibility criteria
We considered all studies that met with the following criteria for our PICOS (Population/Intervention/Comparison/Outcome/Study type) evidence-based research question: (1) patients: individuals with any grade of HE, (2) intervention: PEG, (3) comparator: lactulose, (4) outcomes: reliable data extraction of at least one of our efficacy or safety endpoints and (5) study design: RCTs. We excluded non-randomised studies, conference abstracts, reviews, unpublished RCTs and trials that combined PEG with lactulose as an intervention group. Of note, all included RCTs were open to patients with HE of any grade.

Screening of results
We exported citations from all databases to EndNote software and omitted duplicates. Then, we screened the citations in two steps. We first screened titles and abstracts, and second examined the full texts of potential citations for final inclusion in meta-analysis. Two authors screened the citations and conflicts were resolved by consultation with a third author.

Risk of bias assessment of the included studies
We assessed the risk of bias of included studies according to Cochrane’s risk of bias tool.17 This tool judges the following seven domains: (1) random sequence generation, (2) allocation concealment, (3) binding of participants and personnel, (4) binding of outcome assessment, (5) incomplete outcome data, (6) selective outcome reporting and (7) other potential sources of bias. We scored each domain as unclear, low or high risk. Two authors performed the risk of bias assessment and conflicts were resolved by consultation with a third author.

Data extraction
We extracted baseline characteristics of the included studies, such as first author’s name, country, year of publication, study groups, sample sizes, gender, age, cause of liver cirrhosis and precipitant of HE. With regard to efficacy endpoints, we extracted the following: the average HESA Score at 24 hours post treatment, proportion of patients with reduction of HESA Score by ≥1 grade at 24 hours post treatment, proportion of patients with a HESA Score of grade 0 at 24 hours post treatment, length of hospital stay and time to resolution of HE. With regard to safety endpoints, we extracted the following: frequency of patients with hypokalemia and frequency of death. HESA Score is a widely accepted instrument to grade the severity of HE.7 Resolution of HE was defined as the reduction of at least one grade of HESA Score at 24 hours post treatment. Hypokalemia was defined as concentration level less than 5 μmol/L at 24 hours post treatment.

Data analysis
We used Review Manager software V.5.4.0 for statistical analysis. We analysed dichotomous and continuous data using the Mantel-Haenszel and inverse variance methods, respectively. We pooled the outcomes as risk ratios (RRs) or weighted mean differences, respectively, with 95% CIs. We considered the fixed and random effects models for homogeneous and heterogeneous pooled outcomes, respectively. Between-study heterogeneity was defined as χ² p<0.1 and I² test>50%. If applicable, we performed a sensitivity analysis to rectify the heterogeneous pooled outcomes. During sensitivity analysis, we would eliminate...
one RCT at a time and recalculate the summary RRs for the remaining RCTs. We did not assess for publication bias using Egger’s funnel plots, because of the small number of included studies.19

RESULTS

Literature search

Figure 1 displays the PRISMA diagram. Our literature search yielded a total of 148 citations, of which 64 citations were identified as duplicates. Afterward, we screened the titles and abstracts of the remaining 84 citations and only 6 citations were advanced to full-text screening. Finally, only four RCTs met our inclusion criteria and were included in the qualitative and quantitative analysis.12–15

The baseline characteristics of the included studies are depicted in Table 1. Overall, there were a total of 229 patients (121 and 108 patients received PEG and lactulose, respectively).

Risk of bias assessment

Overall, all studies, except one,20 provided adequate details regarding random sequence generation and allocation concealment. Moreover, all studies were designed as open label and we scored the performance bias domain as high risk. Figure 2 depicts the risk of bias summary and graph of all included studies.

Efficacy endpoint: average HESA Score at 24 hours post treatment

Two RCTs were analysed, comprising a total of 98 patients (PEG=48, lactulose=50). The pooled effect size demonstrated a significantly lower average HESA Score at 24 hours post treatment in favour of the PEG group (MD=−0.68, 95% CI (−1.05 to −0.31), p<0.001). The pooled results were homogeneous (I²=0%, p=0.67) (figure 3A).

Efficacy endpoint: proportion of patients with reduction of HESA Score by ≥1 grade at 24 hours post treatment

Two RCTs were analysed, comprising a total of 148 patients (PEG=73, lactulose=75). The pooled effect size demonstrated a significantly higher proportion of patients with reduction of HESA Score by ≥1 grade at 24 hours post treatment in favour of the PEG group (RR=1.40, 95% CI (1.17 to 1.67), p<0.001). The pooled results were homogeneous (I²=21%, p=0.26) (figure 3B).

Efficacy endpoint: proportion of patients with a HESA Score of grade 0 at 24 hours post treatment

Two RCTs were analysed, comprising a total of 150 patients (PEG=75, lactulose=75). The pooled effect
size demonstrated a significantly higher proportion of patients with a HESA Score of grade 0 at 24 hours post treatment in favour of the PEG group (RR=4.33, 95% CI (2.27 to 8.28), p<0.001). The pooled results were homogeneous (I^2=0%, p=0.82) (figure 3C).

**Efficacy endpoint: time to resolution of HE**

Two RCTs were analysed, comprising a total of 150 patients (PEG=75, lactulose=75). The pooled effect size demonstrated a significantly shorter time to resolution of HE in favour of the PEG group (MD=−1.45, 95% CI (−1.72 to −1.18), p<0.001). The pooled results were homogeneous (I^2=0%, p=0.32) (figure 3D). Rahimi et al reported that the median time to resolution of HE was significantly shorter in favour of the PEG group compared with lactulose group (1 day vs 2 days, p=0.01, respectively).

**Efficacy endpoint: length of hospital stay**

Four RCTs were analysed, comprising a total of 294 patients (PEG=147, lactulose=147). The pooled effect size did not demonstrate a significant difference in terms of length of hospital stay between both groups (MD=−1.00, 95% CI (−1.99 to −0.01), p=0.05). The pooled results were heterogeneous (I^2=78%, p=0.003) (figure 4A). Between-study heterogeneity was best resolved on the omission of the study by Shehata et al and the repooled effect size failed to demonstrate a significant difference between both groups (MD=−0.55, 95% CI (−1.54 to 0.44), p=0.27; heterogeneity: I^2=50%, p=0.14) (figure 4B).

**Safety endpoint: frequency of patients with hypokalemia at 24 hours post treatment**

Two RCTs were analysed, comprising a total of 144 patients (PEG=72, lactulose=72). The pooled effect size did not demonstrate a significant difference between both groups with regard to the frequency of patients with hypokalemia at 24 hours post treatment (RR=0.50, 95% CI (0.13 to 1.94), p=0.32). The pooled results were homogeneous (I^2=0%, p=0.75) (figure 5A).

**Safety endpoints: frequency of death**

Two RCTs were analysed, comprising a total of 150 patients (PEG=100, lactulose=100). The pooled effect size did not demonstrate a significant difference between both groups with regard to the frequency of death (RR=0.50, 95% CI (0.13 to 1.94), p=0.32). The pooled results were homogeneous (I^2=0%, p=1.00) (figure 5B).
**DISCUSSION**

Despite improved knowledge on the pathophysiology of HE, the therapeutic options available for HE has experienced only mild changes with non-absorbable disaccharides being the first line of treatment. PEG is an inexpensive, safe and widely used medication for the treatment of constipation and its use in HE has recently caught the attention of multiple investigators. This meta-analysis is the first one in the literature to compare the effect of PEG versus lactulose in the management of HE. Our analysis has showed that the use of PEG compared with lactulose in patients with HE resulted in a significantly lower average HESA Score at 24 hours post treatment in favour of the PEG group. Additionally, a significantly higher proportion of patients in the PEG group had a reduction of HESA Score by ≥1 grade at 24 hours post treatment compared with lactulose and a significantly higher proportion of patients in the PEG group had HESA Score of grade 0 at 24 hours. In fact, two studies by Naderian et al. and Ahmed et al. compared the concomitant use of PEG with lactulose versus lactulose and concluded that the combination had led to a higher 24 hours HESA Score change as well as a higher reduction in HESA Score by more than one grade at 24 hours post treatment.

The mechanism by which PEG improved HESA Score remains debatable. It has been revealed that lactulose works by reducing intestinal ammonia production and...
absorption leading to an improvement in HE; however, when comparing ammonia levels 24 hours after administration of PEG or lactulose, two trials showed that lactulose was associated with a higher drop in the mean ammonia level compared with patients that were in the PEG group, suggesting that improvement in symptoms of HE in patients that were given PEG was not entirely due to clearance of ammonia. It is important to note that the serum ammonia level does not always correlate with the severity of clinical symptoms, and clinical analysis has showed that lactulose was related to a non-response rate as high as 22%. HE-related hospitalisation costs continue to rise; these costs escalated from $4.68 billion in 2005 to $7.25 billion

Figure 3  Forest plot for meta-analysis of average HESA Score at 24 hours post treatment (A), proportion of patients with reduction of HESA Score by ≥1 grade at 24 hours post treatment (B), proportion of patients with a HESA Score of grade 0 at 24 hours post treatment (C) and time to resolution of HE (D). HESA, Hepatic Encephalopathy Scoring Algorithm; PEG, polyethylene glycol.
in 2009.\textsuperscript{3} Our analysis showed that patients treated with PEG had a significantly shorter time to resolution of HE. Naderian et al\textsuperscript{21} found that patients treated with PEG and lactulose had a shorter mean hospital stay of 6.8 days compared with patients treated with lactulose alone (mean 8.9 days). These results were also validated by Ahmed et al\textsuperscript{22} who found that patients treated with both PEG and lactulose had a mean hospital stay of 9 days compared with 13 days in patients treated with lactulose alone. However, despite the fact that the studies included in this analyses\textsuperscript{8–11} commented on the shorter length of hospital stay even after omitting one study to create a more homogenous group. Accordingly, while the use of PEG contributed to a faster reduction in HESA Score and faster resolution of HE, however, it failed to show a statistical significance in terms of shorter length of hospital stay.

An important consideration with the use of PEG is that it causes substantial catharsis and in theory may lead to dehydration and electrolyte instabilities. However, our study has showed that there was no difference between both groups with regard to the frequency of patients with hypokalemia at 24 hours post treatment. The use of PEG in HE was considered safe and tolerable and was not associated with major serious adverse events. The adverse events reported were gastrointestinal in nature such as diarrhoea, nausea and abdominal distension.\textsuperscript{12 13} In three of the studies, one patient in each study receiving PEG died, however, the cause of death was not related to the intervention itself and our study showed that there was no significant difference between both groups with regard to the frequency of death.

Some limitations still existed in our meta-analysis. First, we included a small number of studies with a small number of patients. When comparing clinical improvement with changes in the HESA, the forest plots only compared two studies and therefore the numbers were low. We also did not include trials comparing the combination of PEG with lactulose versus lactulose as the aim of the study was to compare the two interventions ‘head’ to ‘head’. Larger RCTs are still needed to validate the results. Second, there was some clinical heterogeneity in our study. This may be attributed to one trial\textsuperscript{12} where its protocol stipulated that potential participants could be treated with a single dose of lactulose prior to randomisation, thus patients in the PEG group might have received lactulose before being assigned to the PEG group. Also, in consideration of small number of RCTs per outcome, the degree of between-study homogeneity should be interpreted with caution.\textsuperscript{25} Third, although our analysis showed that patients in the PEG group had faster resolution of HE, it is important to note that for ethical considerations, the trials were designed to avoid delay of standard of care for more than 24 hours at which point patients received lactulose. Whether the faster resolution of HE is due to PEG alone or from the combination of both PEG and lactulose is unknown. Fourth, since the number of included studies was low (less than 10 RCTs), we did not perform publication bias analysis and hence our results could be liable to bias in the reported outcomes.

In conclusion, compared with the standard of care lactulose, a single dose of PEG significantly improved the 24 hours HESA Score and reduced the number of days for HE resolution. Since PEG is safe, widely used and easy to administer, the use of PEG should be considered in the treatment of HE, however further studies are required to validate these result and better understand its effect on encephalopathy-related quality of life.

**Figure 5** Forest plot for meta-analysis of safety endpoints namely frequency of patients with hypokalemia at 24 hours post treatment (A) and frequency of death (B). M-H, Mantel-Haenszel; PEG, polyethylene glycol.
REFERENCES

1 Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. *Hepatology* 2002;35:716–21.

2 Cordoba J. Hepatic encephalopathy: from the pathogenesis to the new treatments. *ISRN Hepatol* 2014;2014:1–16.

3 Stepanova M, Mishra A, Venkatesan C, et al. In-Hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. *Clin Gastroenterol Hepatol* 2012;10:1034–41.

4 Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. *Gastroenterology* 1977;2:573–83.

5 Cordoba J. New assessment of hepatic encephalopathy. *J Hepatol* 2011;54:1030–3.

6 Huda A, Guze BH, Thomas A, et al. Clinical correlation of neuropsychological tests with 1H magnetic resonance spectroscopy in hepatic encephalopathy. *Psychosom Med* 1998;60:550–6.

7 Hassanean T, Hilsabeck RC, Perry W. Introduction to the hepatic encephalopathy scoring algorithm (HESA). *Dig Dis Sci* 2008;53:529–38.

8 Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. *Hepatol Int* 2013;7:359–66.

9 Dawson AM, Sherlock S, Summerskill WH. The treatment and prognosis of hepatic coma. *Lancet* 1956;271:689–94.

10 Bircher J, Haemmerli UP, Scollo-Lavizzari G, et al. Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature. *Am J Med* 1971;51:148–59.

11 Als-Nielsen B, Glud LL, Glud C. Nonabsorbable disaccharides for hepatic encephalopathy. *Cochrane Database Syst Rev* 2004;CD003044.

12 Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs polymethyl glycine 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. *JAMA Intern Med* 2014;174:1727–33.

13 Shehata HH, Effert AA, Abdin AA, et al. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. *Eur J Gastroenterol Hepatol* 2018;30:1476–81.

14 Baijwa KN AB, Nazar T. Comparison of the effectiveness and safety profile of polyethylene Glycol-Electrolyte solution with lactulose in patients of overt hepatic encephalopathy. *PJ M H S* 2019;13:411–4.

15 Raja WJR, Sebastian B, Mathai SK A. To compare the effect of polyethylene glycol vs. lactulose in the treatment of overt hepatic encephalopathy. *Psychother* 2015;62:437–45.

16 Moher D, Liberati A, Tetzlafi J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.

17 Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.

18 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.

19 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.

20 Abu-Zaid A, Alakhtar AM, Alshamidin FD, et al. Thoracic duct cyst presenting as abdominal pain. *Surgery* 2018;163:1324.

21 Naderian M, Akbari H, Saeedi M, et al. Polyethylene glycol and lactulose versus lactulose alone in the treatment of hepatic encephalopathy in patients with cirrhosis: a non-inferiority randomized controlled trial. *Middle East J Dig Dis* 2017;9:12–19.

22 Ahmed S, Premkumar M, Dhiman RK, et al. Combined PEG3350 plus lactulose results in early resolution of hepatic encephalopathy and improved 28-day survival in acute-on-chronic liver failure. *J Clin Gastroenterol* 2020, doi:10.1097/MGC.0000000000001450. [Epub ahead of print: 13 Oct 2020].

23 Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. *J Clin Exp Hepatol* 2015;5:S7–20.

24 Neff G. Pharmaco economics of hepatic encephalopathy. *Pharmacotherapy* 2010;30:28S–32.

25 von Hippel PT. The heterogeneity statistic (I2) can be biased in small meta-analyses. *BMC Med Res Methodol* 2015;15:35.